12 Best Stocks to Buy According to Billionaire David Abrams

11. Nuvation Bio Inc. (NYSE:NUVB)

Abrams Capital Management’s Stake: $34 Million

Nuvation Bio Inc. (NYSE:NUVB) has been featured in the 13F portfolio of Abrams Capital Management since the first quarter of 2021. The stake comprises 3.81 million shares. The fund has not made any changes to this position for the past five years. Nuvation is a clinical-stage biopharmaceutical company that focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. In earnings for the fourth quarter of 2025, the firm announced several strategic advances, including approval and partnerships for IBTROZI in China and Japan, and a new partnership with Eisai for Europe and other territories, with the goal to submit for European approval in the first half of 2026.

Colleen Sjogren, the CCO of Nuvation Bio Inc. (NYSE:NUVB), spoke during the earnings call, highlighting that IBTROZI treated 432 new patients from approval through year-end and is being prescribed across both TKI-naive and pretreated populations. Meanwhile, Philippe Sauvage, the CFO of the biotech company, underlined that out of the $41.9 million in fourth-quarter revenue, $15.7 million was from IBTROZI. Although the management of the firm did not provide specific 2026 revenue guidance, it did underscore confidence in continued first-line patient growth and IBTROZI’s expanding presence.